This webinar discusses the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.

Sarcomas are a group of more than 70 cancers of mesenchymal origin that together comprise approximately 1 percent of all cancers. On initial presentation, these tumors are often localized and curable. Surgery is the mainstay of therapy, but radiation and sometimes chemotherapy can also play an important role.

Unfortunately, even with state-of-the-art care, more than 50 percent of patients with large, high-grade tumors will develop advanced disease. Immunotherapy has the potential to cure many of these patients, but little is known about the changing immune microenvironment during neoadjuvant treatment for soft tissue sarcoma.

During this webinar, Seth M. Pollack of Fred Hutchinson Cancer Research Center discusses a study that used multiple approaches to generate a molecular profile of these cancers. He provides details of how Cofactor Genomics' Paragon assay was used to dissect the changing tumor immune microenvironment in soft tissue sarcoma during neoadjuvant therapy and share results from the study.